Hurlow Wealth Management Group Inc. Invests $170,000 in TuHURA Biosciences (NASDAQ:HURA)

Hurlow Wealth Management Group Inc. purchased a new stake in TuHURA Biosciences (NASDAQ:HURA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 41,444 shares of the company’s stock, valued at approximately $170,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Apollon Wealth Management LLC purchased a new stake in shares of TuHURA Biosciences during the fourth quarter worth $253,000. Charles Schwab Investment Management Inc. bought a new stake in shares of TuHURA Biosciences during the 4th quarter valued at $61,000. Suncoast Equity Management purchased a new stake in TuHURA Biosciences during the 4th quarter worth about $421,000. Accent Capital Management LLC purchased a new position in TuHURA Biosciences during the 4th quarter valued at about $29,000. Finally, Geode Capital Management LLC bought a new stake in TuHURA Biosciences during the 4th quarter worth approximately $1,084,000. 0.62% of the stock is owned by institutional investors.

TuHURA Biosciences Stock Performance

Shares of NASDAQ:HURA opened at $3.40 on Friday. The business has a fifty day moving average of $3.44. TuHURA Biosciences has a one year low of $1.80 and a one year high of $7.93.

Analysts Set New Price Targets

A number of research analysts have recently commented on HURA shares. HC Wainwright reduced their price target on shares of TuHURA Biosciences from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday. Rodman & Renshaw assumed coverage on TuHURA Biosciences in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company. Finally, RODMAN&RENSHAW raised TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th.

TuHURA Biosciences Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.